Trial Profile
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Secukinumab to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Psoriatic Arthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Jan 2023
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary) ; Secukinumab (Primary)
- Indications Plaque psoriasis; Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Acronyms FUTURE-1
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 28 Dec 2022 Results of pooled analysis (n=1554) of two studies (FUTURE 1 & FUTURE 5) assessing quantify the prevalence and extent of pre-existing radiographic damage at baseline; investigate the association of radiographic damage with swollen/tender joint counts at baseline; and investigate the extent to which RD at baseline correlated with response to secukinumab, published in the Arthritis Research and Therapy.
- 14 Nov 2022 Serum samples for analyses of proteomics data from FUTURE 1, 3, 4, and 5 studies were presented at the ACR Convergence 2022.
- 07 Jan 2021 Results of a modelling study from two studies: FUTURE-1(n=539) and FUTURE-5(n=926) assessing predictors of progression and effect of secukinumab on inhibition of structural damage in PsA in subgroups of patients with different underlying rates of progression published in the Clinical and Experimental Rheumatology